Literature DB >> 20097152

Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys.

David E Clements1, Beth-Ann G Coller, Michael M Lieberman, Steven Ogata, Gordon Wang, Kent E Harada, J Robert Putnak, John M Ivy, Michael McDonell, Gary S Bignami, Iain D Peters, Julia Leung, Carolyn Weeks-Levy, Eileen T Nakano, Tom Humphreys.   

Abstract

Truncated recombinant dengue virus envelope protein subunits (80E) are efficiently expressed using the Drosophila Schneider-2 (S2) cell expression system. Binding of conformationally sensitive antibodies as well as X-ray crystal structural studies indicate that the recombinant 80E subunits are properly folded native-like proteins. Combining the 80E subunits from each of the four dengue serotypes with ISCOMATRIX adjuvant, an adjuvant selected from a set of adjuvants tested for maximal and long lasting immune responses, results in high titer virus neutralizing antibody responses. Immunization of mice with a mixture of all four 80E subunits and ISCOMATRIX adjuvant resulted in potent virus neutralizing antibody responses to each of the four serotypes. The responses to the components of the tetravalent mixture were equivalent to the responses to each of the subunits administered individually. In an effort to evaluate the potential protective efficacy of the Drosophila expressed 80E, the dengue serotype 2 (DEN2-80E) subunit was tested in both the mouse and monkey challenge models. In both models protection against viral challenge was achieved with low doses of antigen in the vaccine formulation. In non-human primates, low doses of the tetravalent formulation induced good virus neutralizing antibody titers to all four serotypes and protection against challenge with the two dengue virus serotypes tested. In contrast to previous reports, where subunit vaccine candidates have generally failed to induce potent, protective responses, native-like soluble 80E proteins expressed in the Drosophila S2 cells and administered with appropriate adjuvants are highly immunogenic and capable of eliciting protective responses in both mice and monkeys. These results support the development of a dengue virus tetravalent vaccine based on the four 80E subunits produced in the Drosophila S2 cell expression system. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20097152      PMCID: PMC2837772          DOI: 10.1016/j.vaccine.2010.01.022

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  63 in total

1.  Conformational changes of the flavivirus E glycoprotein.

Authors:  Ying Zhang; Wei Zhang; Steven Ogata; David Clements; James H Strauss; Timothy S Baker; Richard J Kuhn; Michael G Rossmann
Journal:  Structure       Date:  2004-09       Impact factor: 5.006

2.  Transformation of mammalian cells with genes from procaryotes and eucaryotes.

Authors:  M Wigler; R Sweet; G K Sim; B Wold; A Pellicer; E Lacy; T Maniatis; S Silverstein; R Axel
Journal:  Cell       Date:  1979-04       Impact factor: 41.582

3.  Identification of distinct antigenic determinants on dengue-2 virus using monoclonal antibodies.

Authors:  M K Gentry; E A Henchal; J M McCown; W E Brandt; J M Dalrymple
Journal:  Am J Trop Med Hyg       Date:  1982-05       Impact factor: 2.345

4.  Cell lines derived from late embryonic stages of Drosophila melanogaster.

Authors:  I Schneider
Journal:  J Embryol Exp Morphol       Date:  1972-04

5.  A plaque reduction test for dengue virus neutralizing antibodies.

Authors:  P K Russell; A Nisalak; P Sukhavachana; S Vivona
Journal:  J Immunol       Date:  1967-08       Impact factor: 5.422

6.  Isolation of a temperature-sensitive dengue-2 virus under conditions suitable for vaccine development.

Authors:  K H Eckels; W E Brandt; V R Harrison; J M McCown; P K Russell
Journal:  Infect Immun       Date:  1976-11       Impact factor: 3.441

7.  Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand.

Authors:  Timothy P Endy; Ananda Nisalak; Supamit Chunsuttitwat; David W Vaughn; Sharone Green; Francis A Ennis; Alan L Rothman; Daniel H Libraty
Journal:  J Infect Dis       Date:  2004-03-01       Impact factor: 5.226

Review 8.  Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis.

Authors:  Ching-Juh Lai; Thomas P Monath
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

Review 9.  Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.

Authors:  Bruno Guy; Farshad Guirakhoo; Veronique Barban; Stephen Higgs; Thomas P Monath; Jean Lang
Journal:  Vaccine       Date:  2009-10-04       Impact factor: 3.641

10.  Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion.

Authors:  S B Halstead
Journal:  Yale J Biol Med       Date:  1970-04
View more
  68 in total

1.  The necessity and quandaries of dengue vaccine development.

Authors:  Stephen J Thomas
Journal:  J Infect Dis       Date:  2011-02-01       Impact factor: 5.226

2.  Tick-borne Encephalitis Vaccines.

Authors:  Axel T Lehrer; Michael R Holbrook
Journal:  J Bioterror Biodef       Date:  2011

3.  Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques.

Authors:  Jorge E Osorio; Joseph N Brewoo; Shawn J Silengo; John Arguello; Ioana R Moldovan; Magdalena Tary-Lehmann; Tim D Powell; Jill A Livengood; Richard M Kinney; Claire Y-H Huang; Dan T Stinchcomb
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

4.  Dengue vaccine: come let's fight the menace.

Authors:  Sumit Chawla; Soumya Swaroop Sahoo; Inderjeet Singh; Madhur Verma; Vikas Gupta; Sneh Kumari
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Detection, phenotyping and quantification of dengue virus-specific B cells using fluorescent probes.

Authors:  Heather Friberg; Anuja Mathew
Journal:  Hum Vaccin Immunother       Date:  2017-06-12       Impact factor: 3.452

6.  Production of dengue virus envelope protein domain III-based antigens in tobacco chloroplasts using inducible and constitutive expression systems.

Authors:  Johanna Gottschamel; Andreas Lössl; Stephanie Ruf; Yanliang Wang; Morten Skaugen; Ralph Bock; Jihong Liu Clarke
Journal:  Plant Mol Biol       Date:  2016-04-26       Impact factor: 4.076

Review 7.  Viral kinetics of primary dengue virus infection in non-human primates: a systematic review and individual pooled analysis.

Authors:  Benjamin M Althouse; Anna P Durbin; Kathryn A Hanley; Scott B Halstead; Scott C Weaver; Derek A T Cummings
Journal:  Virology       Date:  2014-02-14       Impact factor: 3.616

8.  Formation of Virus-Like Particles of the Dengue Virus Serotype 2 Expressed in Silkworm Larvae.

Authors:  Doddy Irawan Setyo Utomo; Ichikawa Hirono; Tatsuya Kato; Enoch Y Park
Journal:  Mol Biotechnol       Date:  2019-11       Impact factor: 2.695

9.  Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adults.

Authors:  Susan B Manoff; Michele Sausser; Amy Falk Russell; Jason Martin; David Radley; Donna Hyatt; Christine C Roberts; Jason Lickliter; Janakan Krishnarajah; Andrew Bett; Sheri Dubey; Tyler Finn; Beth-Ann Coller
Journal:  Hum Vaccin Immunother       Date:  2019-06-03       Impact factor: 3.452

10.  Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.

Authors:  Ge Liu; Langzhou Song; David W C Beasley; Robert Putnak; Jason Parent; John Misczak; Hong Li; Lucia Reiserova; Xiangyu Liu; Haijun Tian; Wenzhe Liu; Darlene Labonte; Lihua Duan; Youngsun Kim; Linda Travalent; Devin Wigington; Bruce Weaver; Lynda Tussey
Journal:  Clin Vaccine Immunol       Date:  2015-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.